Serca–VivarRios CaBI19 vaccine: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 18: | Line 18: | ||
| notes = | | notes = | ||
}} | }} | ||
The '''Serca–VivarRios CaBI19 vaccine''', also sold under the brand name '''CabiShield''', is a [[Carloso|Carlosian]] toxoid-based vaccine being developed against the [[CaBI19 pandemic|''Clostroides abaddoni'' bacterial infection 2019]] (CaBI19) disease. | The '''Serca–VivarRios CaBI19 vaccine''', also sold under the brand name '''CabiShield''', is a [[Carloso|Carlosian]] toxoid-based vaccine being developed against the [[CaBI19 pandemic|''Clostroides abaddoni'' bacterial infection 2019]] (CaBI19) disease. It is an evolution of efforts to develop a vaccine for ''Clostridioides difficile'' infection (CDI). Interim results indicate an efficacy of 95% against CaBI19. | ||
==Notes== | ==Notes== | ||
Revision as of 19:38, 27 April 2021
 | This article or section is in the process of an expansion or major restructuring. You are welcome to assist in its construction by editing it as well. If this article or section has not been edited in several days, please remove this template. If you are the editor who added this template and you are actively editing, please be sure to replace this template with {{in use}} during the active editing session. Click on the link for template parameters to use.
This article was last edited by Greater Carloso (talk | contribs) 3 years ago. (Update timer) |
 | |
| Type | Toxoid-based vaccine |
|---|---|
| Inventor | Serca Circuit University VivarRios Pharmaceuticals |
| Manufacturer | VivarRios Pharmaceuticals |
| Available | In Phase III trials in Carloso and some other countries |
| Models made | CabiShield |
The Serca–VivarRios CaBI19 vaccine, also sold under the brand name CabiShield, is a Carlosian toxoid-based vaccine being developed against the Clostroides abaddoni bacterial infection 2019 (CaBI19) disease. It is an evolution of efforts to develop a vaccine for Clostridioides difficile infection (CDI). Interim results indicate an efficacy of 95% against CaBI19.